LifeMD (NASDAQ:LFMD - Get Free Report) had its price objective lowered by HC Wainwright from $9.00 to $6.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 234.26% from the stock's current price.
LFMD has been the topic of a number of other reports. Weiss Ratings restated a "sell (d)" rating on shares of LifeMD in a research note on Monday, November 2nd. Zacks Research upgraded LifeMD from a "strong sell" rating to a "hold" rating in a research report on Monday, August 17th. Lake Street Capital reduced their target price on LifeMD from $5.00 to $3.00 and set a "buy" rating for the company in a report on Friday, November 13th. KeyCorp set a $5.00 target price on LifeMD and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, BTIG Research decreased their target price on shares of LifeMD from $10.00 to $9.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, LifeMD presently has a consensus rating of "Moderate Buy" and an average price target of $6.71.
View Our Latest Research Report on LFMD
LifeMD Stock Performance
LFMD stock opened at $1.79 on Wednesday. LifeMD has a one year low of $1.60 and a one year high of $5.38. The stock has a market capitalization of $86.75 million, a PE ratio of -29.92 and a beta of 2.19. The company has a fifty day moving average of $2.55 and a 200-day moving average of $3.56.
LifeMD (NASDAQ:LFMD - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The business had revenue of $44.63 million for the quarter, compared to analyst estimates of $48.84 million. LifeMD had a negative net margin of 0.25% and a negative return on equity of 188.63%. Equities analysts forecast that LifeMD will post -0.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On LifeMD
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of LifeMD by 8.0% in the second quarter. BlackRock Inc. now owns 3,034,535 shares of the company's stock valued at $12,533,000 after buying an additional 225,510 shares in the last quarter. State Street Corp raised its stake in shares of LifeMD by 22.6% during the 2nd quarter. State Street Corp now owns 1,318,784 shares of the company's stock worth $5,447,000 after buying an additional 243,376 shares during the last quarter. Marshall Wace LLP boosted its position in shares of LifeMD by 45.1% in the 3rd quarter. Marshall Wace LLP now owns 809,138 shares of the company's stock worth $2,347,000 after buying an additional 251,664 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of LifeMD in the 2nd quarter worth about $1,338,000. Finally, Russell Investments Group Ltd. boosted its position in shares of LifeMD by 5,801.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company's stock worth $1,300,000 after buying an additional 309,436 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company's stock.
About LifeMD
(
Get Free Report)
LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men's health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LifeMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.
While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.